Skip to content
Homepage
Author:
Tarsus Pharmaceuticals, Inc
Posted Date:
July 8, 2026
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
Tarsus Pharmaceuticals, Inc
July 8, 2026
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc
May 28, 2026
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
Tarsus Pharmaceuticals, Inc
May 14, 2026
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc
May 7, 2026
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals, Inc
May 6, 2026
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Tarsus Pharmaceuticals, Inc
April 29, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Tarsus Pharmaceuticals, Inc
March 31, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals, Inc
March 23, 2026
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc
February 26, 2026
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals, Inc
February 23, 2026
1
2
Next
